Summary
Aim of the study: To evaluate various symptoms/findings for their ability as prognostic markers in MTX-therapy in patients with rheumatoid arthritis.
Patients and methods: 48 patients with definite RA were treated with MTX in a dose of 7,5 to 10 mg weekly for one year. Before MTX-therapy, six and twelve months after initiation of treatment the following examinations were recorded: duration of morning stiffness, grip strength, functional class according to Steinbrocker, Ritchie's Index, ESR, blood count, C-reactive protein, rheumatoid factor, antinuclear antibodies, electrophoresis, ALAT, ASAT, LDH, γ-GT, alkaline phosphatase, uric acid, BUN, serum creatinine and urine analysis. In 29 patients additionnally IL-1α, IL-1β, IL-2, sIL-2-R, IL-6, IL-8, IL-8AB and sCD-8 were determined at the start and after twelve months of treatment.
Statistical analysis was performed by means of a standard SAS programme. Results: After one year 62,5% of the patients showed good or moderate improvement of the disease. In 11 patients minor side effects were observed, in 6 patients (12,5%) treatmet had to be terminated because of side effects.
Good results with MTX were independent of duration of disease, sex, age, grip strength, joint score and seropositivity, but depended significantly on the functional capacity: patients with minor handicap had the greatest benefit from the treatment. Independent of the functional capacity patients with high levels of IL-1β and low levels of IL-8 antibodies both showed favourable results as well. Conclusion: The prediction of the outcome of a treatment with a disease modifying anti rheumatic drug in a single patient is highly desirable. For MTX it could well be worth studying IL-1β and IL-8-antibody levels in a larger group of patients before initiation of MTX therapy to confirm these preliminary results.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Arnett, F.C., Edworthy, S.M., Bloch, D.A., McShane, D.J., Fries, J.F., Medsger, Jr.T.A., Mitchell, D.M., Neustadt, D.H., Pinals, R.S., Schaller, J.-G., Sharp, J.T., Wilder, R.L., Hunder, G.G. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988, 31, 315–324.
Arnold, M.H., O'Callaghan, J., McCredie, M., Beller, E.M., Kelly, D.E., Brooks, P.M. Comparative controlled trial of low-dose weekly methotrexate versus azathioprine in rheumatoid arthritis: 3-year prospective study. Br J Rheumatol 1990, 29, 120–125.
Barrera, P., Boerbooms, A.M.T., Janssen E.M., Sauerwein, R.W., Gallati, H., Mulder, J., de Boo, T., Demacker, P.N.M., van de Putte, L.B.A., van der Meer, J.W.M. Circulating soluble tumor necrosis factor receptors, interleukin-2-receptors, tumor necrosis factor α, and interleukin-6 levels in rheumatoid arthritis: longitudinal evaluation during methotrexate and azathioprine therapy. Arthritis Rheum 1993, 36, 1070–1079.
Crilly, A., Madhok, R.. The effects of methotrexate on soluble interleukin-2 receptor levels in rheumatoid arthritis: comment on the article by Barrera et al. Arthritis Rheum 1994, 37, 597–598.
Furst, D.E., Kremer, J.M. Methotrexate in rheumatoid arthritis. Arthritis Rheum 1988, 31, 305–314.
Hanrahan, P.S., Scrivens, G.A., Russel, A.S. Prospective long-term follow-up of methotrexate therapy in rheumatoid arthritis: toxicity, efficacy and radiological progression. Br J Rheumatol 1989, 28, 147–153.
Peichl, P., Ceska, M., Effenberger, F., Haberhauer, G., Broell, H., Lindley, I.J.D. Presence of NAP-1/IL-8 in synovial fluids indicates a possible pathogenic role in rheumatoid arthritis. Scand J Immunol 1991, 34, 333–339.
Peichl, P., Ceska, M., Broell, H., Effenberger, F., Lindley, I.J.D. Human neutrophil activating peptide/interleukin-8 acts as an autoantigen in rheumatoid arthritis. Ann Rheum Dis 1992, 51, 19–22.
Polisson, R.P., Dooley, M.A., Dawson, D.V., Pisetsky, D.S. Interleukin-2 receptor levels in the sera of rheumatoid arthritis patients treated with methotrexate. Arthritis Rheum 1994, 37, 5056.
Rau, R. Methotrexat-Behandlung der chronischen Polyarthritis. Dtsch med Wschr 1987, 112, 1142–1147.
Sany, J., Anaya, J.M., Lussiez, V., Couret, M., Combe, B., Daures, J.-P. Treatment of rheumatoid arthritis with methotrexate: A prospective open long-term study of 191 cases. J Rheumatol 1991, 18, 1323–1327.
SAS/STAT User's Guide, Version 6., 4th Edition, Cary, NC 1989: SAS Institute Inc., 943 pp.
Wolfe, F., Cathey, M.A. Analysis of methotrexate treatment effect in a longitudinal observational study: Utility of cluster analysis. J Rheumatol 1991, 18, 672–677.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Kolarz, G., Mayrhofer, F., Peichl, P. et al. Prognostic factors for the outcome of methotrexate treatment in rheumatoid arthritis. Clin Rheumatol 14, 515–518 (1995). https://doi.org/10.1007/BF02208147
Received:
Revised:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02208147